카르니틴이 비알코올성 지방간 질환에서 말초혈액 미토콘드리아 DNA 단위 반복수와 간기능에 미치는 영향 = Effects of Carnitine on Peripheral Blood Mitochondrial DNA Copy Number and Liver Function in Non-Alcoholic Fatty Liver Disease

다국어 초록 (Multilingual Abstract)

Background/Aims: Functional and anatomical abnormalities of mitochondria play an important role in developing steatohepatitis. Carnitine is essential for enhanced mitochondrial beta oxidation through the transfer of long-chain fatty acids into the mitochondria. We examined the impact of carnitine complex on liver function and peripheral blood mitochondria copy number in NAFLD patients. Methods: Forty-five NAFLD patients were enrolled. Patients were categorized into the carnitine complex-administered group and control group. Before and 3 months after drug administration, a liver function test and peripheral blood mitochondrial DNA and 8-oxo-dG quantitive analysis were conducted. Results: In carnitine treatment group, ALT, AST, and total bilirubin were reduced after medication. There was no difference in AST, ALT, and total bilirubin between before and after treatment in control group. In carnitine group, peripheral mitochondrial DNA copy number was significantly increased from 158.8±69.5 copy to 241.6±180.6 copy (p=0.025). While in control group the mitochondrial copy number was slightly reduced from 205.5±142.3 to 150.0±109.7. 8-oxo-dG level was also tended to decrease in carnitine group (p=0.23) and tended to increase in control group (p=0.07). Conclusions: In NAFLD, the carnitine improved liver profile and peripheral blood mitochondrial DNA copy number. This results suggest that carnitine activate the mitochondria, thereby contributing to the improvement of NAFLD. (Korean J Gastroenterol 2010;55:384-389)

참고문헌 (Reference)

• 1 Kraemer WJ, "The effects of L-carnitine L-tartrate supplementation on hormonal responses to resistance exercise and recovery" 17 : 455-462, 2003
• 2 Kumaran S, "Supplementation of L-carnitine improves mitochondrial enzymes in heart and skeletal muscle of aged rats" 31 : 55-67, 2005
• 3 Berson A, "Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes" 114 : 764-774, 1998
• 4 Wu X, "Prevention of free fatty acid-induced hepatic lipotoxicity by 18beta-glycyrrhetinic acid through lysosomal and mitochondrial pathways" 47 : 1905-1915, 2008
• 5 Krähenbühl S, "Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity" 37 : 140-143, 1995
• 6 Song J, "Peripheral blood mitochondrial DNA content is related to insulin sensitivity in offspring of type 2 diabetic patients" 24 : 865-869, 2001
• 7 Clark JM, "Nonalcoholic fatty liver disease" 122 : 1649-1657, 2002
• 8 Pessayre D, "NASH: a mitochondrial disease" 42 : 928-940, 2005
• 9 Szeto HH, "Mitochondria-targeted peptide antioxidants: novel neuroprotective agents" 8 : E521-531, 2006
• 10 Ibdah JA, "Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance" 128 : 1381-1390, 2005
• 11 Romano M, "L-carnitine treatment reduces steatosis in patients with chronic hepatitis C treated with alpha-interferon and ribavirin" 53 : 1114-1121, 2008
• 12 Bowyer BA, "L-carnitine therapy in home parenteral nutrition patients with abnormal liver tests and low plasma carnitine concentrations" 94 : 434-438, 1988
• 13 Pérez-Carreras M, "Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis" 38 : 999-1007, 2003
• 14 Lee HK, "Decreased mitochondrial DNA content in peripheral blood precedes the development of non-insulin-dependent diabetes mellitus" 42 : 161-167, 1998
• 15 Bremer J, "Carnitine-metabolism and functions" 63 : 1420-1480, 1983